Track Kezar Life Sciences, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Kezar Life Sciences, Inc. KZR · Stock Open Kezar Life Sciences, Inc. in new tab

7.29 USD
EPS
-6.17
P/B
0.76
ROE
-59.93
Beta
0.41
Target Price
6.00 USD
Loading chart...
Key Metrics
Earnings dateAug. 12, 2026
EPS-6.17
Book Value9.56
Price to Book0.76
Debt/Equity3.32
% Insiders15.782%
Estimates
Forward P/E-1.84
Forward EPS-4.66
Target Mean Price6.00

DCF valuation

Model fair value for Kezar Life Sciences, Inc. (KZR)
Result
Sign in to run the valuation for KZR.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 6.00 USD (low 5.00, high 7.00)
Low 5.00
Mean 6.00
High 7.00
Price 7.29
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Kezar Life Sciences, Inc. Logo Kezar Life Sciences, Inc. Analysis (KZR)

United States Health Care Official Website Stock

Is Kezar Life Sciences, Inc. a good investment? Kezar Life Sciences, Inc. (KZR) is currently trading at 7.29 USD. Market analysts have a consensus price target of 6.00 USD. This suggests the asset is currently trading above analyst expectations.

Earnings Schedule: Kezar Life Sciences, Inc. is expected to release its next earnings report on Aug. 12, 2026. The market consensus estimate for Forward EPS is -4.66.

Investor FAQ

Does Kezar Life Sciences, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Kezar Life Sciences, Inc.?

Kezar Life Sciences, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 12, 2026. The company currently has a trailing EPS of -6.17.

Company Profile

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Exchange Ticker
NMS (United States) KZR
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Oct. 30, 2024 1:10
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion